Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: a randomized controlled study

Pengfei Yu, Yian Du, Zhiyuan Xu, Ling Huang and Xiangdong Cheng*

Abstract

Background: The optimal extent of lymph node (LN) dissection for advanced distal gastric cancer remains controversial. The present study compared the safety and efficacy of extended LN dissection (D2 plus) with standard D2 radical surgery for advanced distal gastric cancer.

Methods: Eligible patients were enrolled and randomly assigned into two groups: D2 group and D2 plus group. Patients in the D2 group received standard D2 LN dissection, while patients in the D2 plus group received an additional nos. 8p, 12b, 13, and 14v LNs dissection. The clinicopathological and surgical data of these two groups were compared, and the factors that may influence survival were analyzed.

Results: Seventy patients were enrolled, out of which 64 patients were analyzed. There were no significant differences in the operative time, blood loss, and complications between the two groups. In the D2 plus group, the positive rate of the nos. 12b, 13, and 14v LN was 3.1%, 9.4%, and 12.5%, respectively. The positive rate of the no. 13 LN correlated with the duodenal involvement, while the positive rate of the no. 14v LN correlated with no. 6 LN metastasis. The survival analysis indicated that among patients with duodenum involvement, the 3-year disease-free survival rate of the D2 plus group was significantly better than that of the D2 group.

Conclusion: Duodenum involvement and positive no. 6 LN were high-risk factors of advanced distal gastric cancer. D2 plus radical surgery turned out to be safe and feasible, and may improve the prognosis of these patients. However, further clinical trials are still warranted.

Keywords: Gastric neoplasm, Lymph node dissection, Complications, Metastasis, Prognosis

Background

Gastric cancer is the fifth most common cancer and the third most common cause of cancer death worldwide [1]. Although chemotherapy and targeted therapy have improved the prognosis of advanced gastric cancer, radical surgery remains the most effective treatment strategy [2, 3]. Recurrence or metastasis after radical resection of gastric cancer is frequent with lymph node (LN) metastasis being one of the important reasons [4]. D2 dissection has been regarded as the standard surgical procedure for advanced gastric cancer. However, controversy remains over the extent of LN dissection in gastric cancer with different tumor stages and tumor locations.

Studies have reported that distal gastric cancer can metastasize to the no. 8p, 12b, 13, and 14v LNs due to the specificity of lesions and biological behavior [5–7]. Therefore, determining whether these lymph nodes should be included in the scope of LN dissection (D2 plus) is important. According to the Japanese gastric cancer treatment guidelines, the nos. 13 and 14v LNs are classified as M1 and are not required for D2 radical dissection [8]. However, some patients with metastasis to nos. 13 and 14v LNs had long-term survival after D2 plus LN dissection. Therefore, the clinical significance of D2 plus 8p, 12b, 13, and 14v LN dissection cannot be completely denied in patients with advanced distal...
gastric cancer. Further studies are warranted to clarify the
cellular characteristics of LN metastasis and its impact on prognosis.

The present study aimed to compare the safety and
efficacy of D2 and D2 plus radical surgery and determine
the subgroup of patients with advanced distal gastric cancer
who are likely to benefit from D2 plus LN dissection.

Methods

Study design and patients

This is a randomized controlled, prospective, phase II
study conducted at Zhejiang Cancer Hospital (Hangzhou,
China) in accordance with the Helsinki Declaration and the
good clinical practice guidelines. The study protocol
was approved by the Institutional Ethics Review Board of
Zhejiang Cancer Hospital (approval number: [2013]-01-50). A written informed consent was obtained from
each study participant. This trial was registered with Clini-
calTrials.gov (#NCT01836991).

Enrollment criteria were as follows: (1) patients with ad-
vanced distal gastric adenocarcinoma (including duode-
umin involvement), which was pathologically confirmed by
endoscopic biopsy; (2) absence of distant metastasis; (3)
age 18–80 years and Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2; (4) good general condition with a life expectancy of > 6 months; (5) patients
with alanine transaminase (ALT) and aspartate transam-
inasen (AST) levels less than two times the upper limit of the
normal range (ULN), serum total bilirubin < 1.5 times the
ULN, serum creatinine < 1.25 times the ULN, platelet
counts > 75,000/L, absolute granulocyte counts > 1500/L,
hemoglobin levels > 90 g/L, and normal electrocardiogram;
(6) fit to receive R0 surgery with D2 or D2 plus lymphade-
necotomy; (7) did not receive neoadjuvant chemotherapy
and other treatments before the surgery.

The exclusion criteria were as follows: presence of a syn-
chronous or metachronous (within 5 years) malignancy;
pregnant or lactating patients; severe drug hypersensitiv-
ity; mental abnormalities; the systemic administration of
corticosteroids; severe respiratory disease; uncontrolled
hypertension, diabetes mellitus, and heart disease.

Surgery

All the eligible patients were enrolled and randomly
assigned into two groups: D2 group and D2 plus group.
All the surgeons who participated in the present trial
had significant experience in gastric cancer surgery, par-
ticularly open distal gastrectomy (at least 50 procedures).
According to the Japanese gastric cancer treatment
guidelines [8], D2 radical surgery (D2 group) for distal
gastric cancer refers to the dissection of nos. 1, 3, 4sb,
4d, 5, 6, 7, 8a, 9, 11p, and 12a LNs. D2 plus radical gas-
trectomy (D2 plus group) refers to the additional en bloc
dissection of hepatoduodenal ligament LNs along the
common bile duct (no. 12b), posterior LNs along the
common hepatic artery (no. 8p), LNs behind the head of
the pancreas (no. 13), and LNs along the superior mes-
enteric vein (no. 14v) (Additional file 1). For patients
with duodenum involvement, Billroth II reconstruction
was usually performed and the lower margin was en-
sured to be negative on frozen section. Patients who re-
quired combined pancreaticoduodenectomy were not
included in the present study.

Analysis

The primary endpoint was the safety of radical surgery,
and the secondary endpoints were 3-year disease-free
survival (DFS) and overall survival (OS).

The following parameters were recorded: patient age
and gender, tumor location, histological type, surgical pro-
cedure, postoperative complications, depth of tumor inva-
sion, and the number of retrieved LNs. The characteristics
of the tumor were recorded according to the Japanese gas-
tric cancer classification (3rd edition) [9] and Union for
International Cancer Control (UICC) TNM classification
(7th edition) [10]. Complications were defined as any
deviation from the normal postoperative course and clas-
sified according to the Clavien-Dindo severity classifica-
tion (CDSG) [11]. Surgical data and the characteristics of
positive LNs were compared between the D2 and D2 plus
group, and the clinicopathological factors that may influ-
ence survival were also analyzed.

Follow-up

All the patients received adjuvant chemotherapy based
on platinum and 5-flourouracil (5-FU) for 4–6 cycles.
Patients underwent routine follow-ups after surgery
once every 3 months within 2 years, and once every
6 months for 2–5 years. The last follow-up was
obtained in April 2018. Postoperative survival time was
calculated from the time of radical gastrectomy to the
end of the last follow-up or death.

Statistical analysis

Mean ± standard deviation or median and range were
used to present the continuous data. Student’s t test and
chi-square test were used to compare continuous and cat-
egorical data, respectively. The Kaplan-Meier method was
used to generate the survival curves, which were com-
pared by log-rank test. Statistical analyses were conducted
using Statistical Package for Social Sciences (SPSS) version
19.0 software (Chicago, IL, USA). All the statistical tests
were two sided, and the differences were considered to be
statistically significant when the P value was < 0.05.

Results

Baseline characteristics

From April 2013 to December 2014, 70 patients were
enrolled in this study. Among these patients, four
patients did not receive surgery, while two patients received combined pancreaticoduodenectomy. A total of 64 patients (32 patients in each group) were included in the analysis. There were 48 males and 16 females with the median age of 59 years (range 25–76 years). Furthermore, 17 patients had stage II disease and 47 patients had stage III disease. The histological types were adenocarcinoma (58 patients), signet ring cell carcinoma (5 patients), and mucinous adenocarcinoma (1 patient) (Table 1).

### Surgical results

All 64 patients received R0 resection. Billroth I (n = 36) and Billroth II (n = 25) were the main reconstruction methods. The mean operative time and blood loss in the D2 plus group were greater than those in the D2 group, but the difference was not statistically significant (mean operative time 179.6 ± 60.7 min vs. 163.3 ± 59.1 min, p = 0.351; mean blood loss 181.3 ± 86.0 ml vs. 158.7 ± 70.4 ml, p = 0.436). A total of 12 (18.75%) postoperative complications occurred (Clavien-Dindo grade II), including ascites (n = 5), pulmonary infection (n = 2), wound infection (n = 2), anastomotic leakage (n = 2), and pancreatic fistula (n = 1). However, there was no statistically significant difference between the two groups (Table 1).

In the D2 plus group, the positive rate of the nos. 8p, 12b, 13, and 14v LNs was 0, 3.1%, 9.4%, and 12.5%, respectively (Table 2). The positive rate of the no. 13 LN correlated with duodenal involvement, while the positive rate of the no. 14v LN correlated with no. 6 LN metastasis. However, the positive rate of the no. 12b LN had not correlated with the depth of invasion, LN metastasis, the duodenal involvement, tumor size, histological type, and other clinicopathological factors (Table 3).

### Treatment toxicity

Adjuvant chemotherapy consisting of platinum and 5-fluorouracil (5-FU) was well-tolerated in most patients. Grade 3 or 4 toxicity occurred in 13 of 64 patients (20.3%). Among these, the most common hematological toxic effects were leukopenia/neutropenia (10.9%) and thrombocytopenia (3.1%) while the most frequent non-hematological toxic effects were elevation of serum aspartate aminotransferase levels (4.7%) and rash (1.6%). There was no statistically significant difference in treatment toxicity between the two groups (Table 4).

### Survival analysis

The mean follow-up period was 39.2 months (10–62 months). A total of 22 patients developed recurrence, while 18 patients died during the follow-up period. The 3-year DFS of the D2 plus group and D2 group were 64.3% and 58.6%, respectively, with no significant difference (P = 0.655). The 3-year OS of the D2 plus group and D2 group were similar (71.4% vs. 65.5%, P = 0.613).

### Table 1 Comparison of clinicopathological factors and surgical data between the D2 and D2 plus group

| Clinicopathological factors | D2 radical surgery (32 cases) | D2 plus radical surgery (32 cases) | P value |
|-----------------------------|-----------------------------|-----------------------------------|--------|
| Gender                      |                             |                                   | 0.564  |
| Male                        | 25                          | 23                                |        |
| Female                      | 7                           | 9                                 |        |
| Age (years)                 |                             |                                   | 0.522  |
| > 50                        | 27                          | 25                                |        |
| ≤ 50                        | 5                           | 7                                 |        |
| Tumor location              |                             |                                   | 0.554  |
| Lower third                 | 30                          | 31                                |        |
| Middle third                | 2                           | 1                                 |        |
| Histological type           |                             |                                   | 0.688  |
| Adenocarcinoma              |                             |                                   |        |
| Poor differentiation        | 13                          | 15                                |        |
| Well-moderate differentiation | 16                        | 14                                |        |
| Signet ring cell carcinoma  | 2                           | 3                                 |        |
| Mucinous adenocarcinoma     | 1                           | 0                                 |        |
| TNM stage                   |                             |                                   | 0.157  |
| II                          | 11                          | 6                                 |        |
| III                         | 21                          | 26                                |        |
| Operation time (min)        | 163.3 ± 59.1                | 179.6 ± 60.7                      | 0.351  |
| Blood loss (ml)             | 158.7 ± 70.4                | 181.3 ± 86.0                      | 0.436  |
| Number of LNs               | 34.8 ± 11.4                 | 39.4 ± 12.0                       | 0.217  |
| Positive LNs               | 4.5 ± 8.5                   | 6.5 ± 7.9                         | 0.509  |
| Postoperative complications |                             |                                   | 0.785  |
| Pulmonary infection         | 1                           | 1                                 |        |
| Wound infection             | 0                           | 2                                 |        |
| Anastomotic leakage         | 1                           | 1                                 |        |
| Pancreatic fistula          | 0                           | 1                                 |        |
| Ascites                     | 1                           | 4                                 |        |
| Hospital stay (days)        | 9.8 ± 2.5                   | 10.5 ± 1.7                        | 0.768  |
D2 group; however, the difference was not statistically significant (69.2% vs. 40.0%, \( P = 0.133 \)) (Fig. 2b).

**Discussion**

Gastric cancer is one of the most common malignancies worldwide [12]. However, its prognosis is very poor despite the advances in the multimodality treatment. Radical surgery has been considered as the main strategy to obtain the exact curative effect for advanced gastric cancer. However, controversy remains on the extent of LN dissection [8]. At present, D2 radical surgery is regarded as the standard surgical procedure for advanced gastric cancer, and there are no consensus on whether an extended LN dissection (D2 plus) should be performed to improve the prognosis [13, 14]. Some researchers have considered that extended LN dissection does not improve the survival and increases the probability of postoperative complications and mortality [15, 16]. However, other studies have shown that extended LN dissection may achieve better results for advanced gastric cancer. Zhang et al. conducted a retrospective study on 567 patients, in which they compared D1 with D3 through D2 lymphadenectomy for gastric cancer [17]. The analysis revealed that in the subgroups of patients with distal gastric cancer, Borrmann II and III, T3 tumors, and clinically LN-positive disease, extended LN dissection could be beneficial without increasing the postoperative complications and mortality. Kumagai et al. reported that in advanced distal gastric cancer with duodenal involvement, there may be survival benefit with the dissection of the no. 12b, 13, 14v, 16a2, and 16b1 LNs [18].

Therefore, a randomized controlled study of D2 radical surgery vs. D2 plus radical surgery was conducted to determine the safety and possible survival benefits of extended LN dissection. This study found that although D2 plus radical surgery was more complicated than D2 radical surgery, there were no significant differences in the mean blood loss and postoperative complications between the two groups. These results are consistent with the previous reports [19, 20]. Therefore, D2 plus radical surgery is safe and feasible.

Studies have shown that advanced distal gastric cancer is prone to metastasize to the nos. 12b, 13, and 14v LNs. Moreover, when distal gastric cancer invades the duodenum, the incidence of metastasis to no. 13 LN can reach up to 23.9% [7]. The probability of metastasis to the no.

| Toxic effects | D2 radical surgery (32 cases) | D2 plus radical surgery (32 cases) | \( P \) value |
|---------------|------------------------------|-----------------------------------|-------------|
| Hematological |                              |                                   |             |
| Leukopenia/neutropenia | 4(12.5%) | 3(9.4%) | 0.689 |
| Thrombocytopenia | 1(3.1%) | 1(3.1%) | 1.000 |
| Non-hematological |                        |                                   |             |
| Transaminase elevation | 2(6.3%) | 1(3.1%) | 0.554 |
| Rash | 1(3.1%) | 0(0%) | 0.314 |

**Table 2** Positive rate of extended dissected LNs in the D2 plus surgery group

| Positive cases | Positive rate (%) |
|---------------|-------------------|
| 8p            | 0                 | 0                 |
| 12b           | 1                 | 3.1               |
| 13            | 3                 | 9.4               |
| 14v           | 4                 | 12.5              |

| Table 3 The relationship between no. 12b, 13, and 14v LNs involvement and clinicopathological factors |
|-----------------------------------------------|-------------------|-------------------|

**Table 4** Grade 3/4 toxic effects in the two groups

| Clinicopathological factors | No. 12b | P value | No. 13 | P value | No. 14v | P value |
|-----------------------------|---------|---------|--------|---------|---------|---------|
| 1 category                  |         |         |        |         |         |         |
| T1–2                        | 0 6     | 0.382   | 0 6    | 0.382   | 0 6     | 0.382   |
| T3–4                        | 1 25    | 0.340   | 3 23   | 0.087   | 4 22    | 0.045   |
| No. 6 LNs                   | 0 15    | 0.400   | 1 15   | 0.335   | 0 15    | 0.135   |
| Negative                    | 0 15    | 0.400   | 1 15   | 0.335   | 0 15    | 0.135   |
| Positive                    | 1 16    | 0.370   | 3 14   | 0.039   | 4 13    | 0.419   |
| Duodenum involvement        |         |         |        |         |         |         |
| No                           | 0 17    | 0.723   | 0 18   | 0.827   | 3 15    | 0.884   |
| Yes                          | 0 14    | 0.723   | 3 11   | 0.827   | 1 13    | 0.884   |
| Tumor size                  |         |         |        |         |         |         |
| ≥ 5 cm                      | 0 13    | 0.400   | 2 11   | 0.335   | 3 10    | 0.135   |
| < 5 cm                      | 1 18    | 0.400   | 1 18   | 0.335   | 1 18    | 0.135   |
| Histological type           |         |         |        |         |         |         |
| Adenocarcinoma              |         |         |        |         |         |         |
| Poorly                      | 1 13    | 0.723   | 2 12   | 0.827   | 2 12    | 0.884   |
| Well-moderately             | 0 14    | 0.723   | 1 13   | 0.827   | 2 12    | 0.884   |
| SRCC                        | 0 3     | 0.723   | 0 3    | 0.827   | 0 3     | 0.884   |
| MAC                         | 0 1     | 0.723   | 0 1    | 0.827   | 0 1     | 0.884   |
| CA19-9 (U/ml)               |         |         |        |         |         |         |
| ≥ 37                        | 0 6     | 0.625   | 0 6    | 0.382   | 1 5     | 0.732   |
| < 37                        | 1 25    | 0.625   | 3 23   | 0.434   | 3 23    | 0.581   |
| CEA (ng/ml)                 |         |         |        |         |         |         |
| ≥ 5                         | 0 5     | 0.662   | 0 5    | 0.434   | 1 4     | 0.581   |
| < 5                         | 1 26    | 0.662   | 3 24   | 0.434   | 3 24    | 0.581   |
| AFP (ng/ml)                 |         |         |        |         |         |         |
| ≥ 10                        | 0 3     | 0.744   | 0 3    | 0.558   | 0 3     | 0.492   |
| < 10                        | 1 28    | 0.744   | 3 26   | 0.558   | 4 25    | 0.492   |

SRCC signet ring cell carcinoma; MAC mucinous adenocarcinoma; CA19-9 carbohydrate antigen 19-9; CEA carcinoembryonic antigen
LN significantly increases in patients with positive no. 6 LN [21]. It was observed that in the cases of D2 plus radical surgery, extended dissected LN had high incidences of metastasis (25%). Also, in patients with duodenal involvement, the local recurrence rate was much higher in the D2 group. Therefore, for advanced distal gastric cancer with high-risk factors such as the involvement of the duodenum or metastasis to the no. 6 LN, merely D2 LN dissection may not be sufficient [19, 22], as positive LNs may remain and cause postoperative recurrence and/or metastasis leading to adverse outcomes.

Our survival analysis revealed that in patients with no. 6 LN metastasis or duodenal involvement, the 3-year OS of the D2 plus group was higher than that of the D2 group, although the difference was not statistically significant ($P > 0.05$).

**Conclusion**

The present study revealed that for advanced distal gastric cancer with high-risk factors such as the involvement of the duodenum or metastasis to the no. 6 LN, merely D2 LN dissection may not be sufficient, as positive LNs may remain and cause postoperative recurrence and/or metastasis leading to adverse outcomes. Further multi-center large sample studies are required to clarify the survival benefits of D2 plus radical surgery for advanced distal gastric cancer with high-risk factors.
the duodenum and metastasis to the no. 6 LN, D2 plus radical surgery may be considered. This procedure is safe and feasible, and does not increase postoperative complications, when compared to D2 radical surgery. However, further clinical trials are warranted to validate the findings of this study.

Additional file

Additional file 1: D2 plus radical surgery for advanced distal gastric cancer. (IRMB 73272 kb)

Abbreviations

S-Flu: 5-flurouracil; ALT: Alanine transaminase; AST: Aspartate transaminase; CDSC: Clavien-Dindo severity classification; DFS: Disease-free survival; ECOG: Eastern Cooperative Oncology Group; LN: Lymph node; OS: Overall survival; UICC: Union for International Cancer Control; ULN: Upper limit of the normal range

Acknowledgements

We thank all the study participants and research staff who participated in this work.

Funding

None.

Availability of data and materials

The present data cannot be made publicly available due to ethical reasons. The data for the present study may be requested by contacting the authors at abdsurg@163.com or Department of Abdominal Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China.

Authors’ contributions

PY, YD, ZX, LH, and XC designed and conducted the study, analyzed the data, and helped to write the manuscript. XC is the principal investigator, and revised and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study protocol was approved by the institutional ethics review board of Zhejiang Cancer Hospital. A written informed consent was obtained from each study participant.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 16 October 2018 Accepted: 27 January 2019
Published online: 06 February 2019

References

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial investigators: trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2012;376:687–97.
3. Chang SC, Liu KH, Hung CY, et al. Adjuvant chemotherapy improves survival in stage III gastric cancer after D2 surgery. J Cancer. 2018;9:81–91.
4. Sasako M. Gastric cancer eastern experience. Surg Oncol Clin N Am. 2012;21:71–7.
5. Wu L, Zhang C, Liang Y, et al. Risk factors for metastasis to no.14v lymph node and prognostic value of 14v status for gastric cancer patients after surgery. Jpn J Clin Oncol. 2018;48:335–42.
6. Du Y, Cheng X, Xu Z, et al. D2 plus radical resection combined with perioperative chemotherapy for advanced gastric cancer with pyloric obstruction. Chin J Cancer Res. 2013;25:479–81.
7. Tokunaga M, Ohyama S, Hiki N, et al. Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenal invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol. 2009;16:1241–6.
8. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver. 4). Gastric Cancer. 2017;20:1–19.
9. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
10. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley-Blackwell; 2010.
11. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
12. Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305.
13. Mocellin S. The effect of lymph node dissection on the survival of patients with operable gastric carcinoma. JAMA Oncol. 2016;2:363–4.
14. Douridas GN, Rierarkakis SK. Is there any role for D3 lymphadenectomy in gastric cancer? Front Surg. 2018;5:27.
15. Bostanci EB, Kayaalp C, Ozogul Y, et al. Comparison of complications after D2 and D3 dissection for gastric cancer. Eur J Surg Oncol. 2004;30:20–5.
16. Bostanci EB, Ozer I, Ercan M, et al. A prospective observational study of 468 patients undergoing D2 or D3 lymphadenectomy for gastric cancer. Hepato-Gastroenterology. 2013;60:264–7.
17. Zhang H, Liu C, Wu D, et al. Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference. BMC Cancer. 2010;10:308.
18. Kurnagia K, Sano T, Hiki N, et al. Survival benefit of “D2-plus” gastrectomy in gastric cancer patients with duodenal invasion. Gastric Cancer. 2018;21:296–302.
19. Eem BW, Joo J, Kim YW, et al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol. 2013;20:2669–75.
20. Eom BW, Joo J, Kim YW, et al. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery. 2014;155:408–16.
21. Liang H, Deng J. Evaluation of rational extent lymphadenectomy for local advanced gastric cancer. Chin J Cancer Res. 2016;28:397–403.
22. Chen QY, Huang CM, Lin JX, et al. Laparoscopic infrayaplic area lymph node dissection with no. 14v enlargement for advanced lower gastric cancer in middle colic vein approach. Ann Surg Oncol. 2016;23:951.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions